Effect of laser biostimulation and a low-calorie diet vs. a low-calorie diet alone on insulin resistance, inflammatory biomarkers, and depression among obese postmenopausal women: a randomized controlled trial

M.M. ELSAYED¹, M. RAKHA², H.A. ELSHEIMY², N.E. ABDELAZIZ², E.N. NAGY¹

¹Department of Physical Therapy for Cardiovascular/Respiratory Disorders and Geriatrics, Faculty of Physical Therapy, Cairo University, Cairo, Egypt

²Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt

Abstract. – OBJECTIVE: Postmenopausal women are significantly predisposed to a multitude of disorders. Laser biostimulation (LB) and a healthy diet have been linked to multiple health benefits. This study aimed to investigate the effect of a combined LB and balanced low-calorie diet (LCD) *vs.* an LCD alone on insulin resistance (IR), inflammatory biomarkers, and depression score in obese postmenopausal women.

PATIENTS AND METHODS: In the present study, a total of 66 postmenopausal women, with a mean age of 66.61 ± 4.80 years and a body mass index (BMI) of 35.93 ± 2.67 kg/m², were randomized into two equal groups. The experimental group received LB and LCD (including 50-60% carbohydrates, 15-20% protein, 20-35% fat, and 25 g of fiber/day plus a restriction of 500-1000 kcal/d), while the control group followed the same diet program only for 12 weeks. Before and after the intervention, IR [measured by the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR index)], inflammatory biomarkers [C-reactive protein (CRP), white blood cells (WBCs), lymphocytes, and erythrocyte sedimentation rate (ESR)], and depression level [as assessed by the Hamilton Depression Rating Scale (HAMD-17)] were all measured.

RESULTS: Using an intention-to-treat analysis for 60 women who completed the study, the body weight average reduction was -13.14% for the experimental group (p<0.001) vs. -6.36% for the control group (p<0.001). BMI, IR, inflammatory markers, and depression levels were also similarly changed.

CONCLUSIONS: In postmenopausal obese women, adding LB to a suitable dietary program provides the most significant benefit in terms of lowering IR, metabolic inflammation, and depression.

Key Words:

Introduction

Globally, women after menopause are more likely to develop metabolic and psychiatric illnesses, which are linked to increased mortality and morbidity rates¹. In Egypt, because of a lack of health facilities, women have a higher rate of menopause-related conditions². For instance, obesity, which is associated with higher insulin resistance (IR) and inflammatory markers [C-reactive protein (CRP), white blood cells (WBCs)¹, lymphocytes, and erythrocyte sedimentation rate (ESR)]³. Moreover, psychiatric disorders are common in postmenopausal women, which reduce immune system response and promote inflammation⁴.

These comorbidities are pervasive in obese postmenopausal women¹ and are associated with elevated drug consumption, thus increasing the risk of adverse events³. Consequently, it is critical to investigate potential non-pharmacological safety interventions that reduce multimorbidity associated with obesity.

Laser biostimulation (LB) and dietary restriction demonstrated more desirable changes in body composition^{5,6}; LB has achieved remarkable results in obesity management⁶, being a non-invasive, quick, and safe intervention that stimulates conventional acupoints⁷. Many studies^{8,9} have identified the role of LB in weight loss.

Furthermore, LB has multiple significant health benefits¹⁰, such as changing cellular metabolic processes and regulating inflammatory mediators¹¹. One of the most recent LB applications is the Laser Watch, which provides laser blood

Anti-inflammatory agents, Blood sedimentation, Caloric restriction, Low-level light therapy, Post-menopause, Risk factors.

irradiation⁷ and has been revealed to improve microcirculation, insulin secretion, lipid profile, and body composition¹⁰.

A well-balanced diet is a crucial component of lifestyle adjustments to lower BMI⁵, inflammatory and metabolic indicators, and cardiovascular risks¹². Accordingly, the current study's purpose was to determine whether a combined LB and low-calorie diet (LCD) demonstrate better outcomes than LCD alone to reduce IR, inflammatory markers, and depression in postmenopausal obese women.

Patients and Methods

Study Design and Ethical Approval

According to the latest CONSORT statement and the Helsinki Declaration, this 12-week parallel randomized clinical trial was conducted on postmenopausal women from January 2020 to January 2021. After fully demonstrating the study's objectives and voluntary purpose, each participant provided written informed consent. Faculty of Physical Therapy Ethics Committee, Cairo University, Egypt approved the study under No. P.T.REC/012/002677.

Study Setting and Participants

A group of eligible postmenopausal women was assessed and enrolled by physicians (MR, HA, and NA; co-authors) from the Internal Medicine Department, outpatient clinic, Cairo University Hospital, Egypt. The participants were recruited in the study based on the following inclusion criteria: selected women had not menstrual cycle for an average of 11.05 ± 2.13 years, had a BMI of 35.93 ± 2.67 kg/m², and were 66.61 ± 4.80 years old. They had moderate depression [8–16 on the Hamilton Depression Rating Scale (HAMD-17)] and a sedentary lifestyle (less than 14 units defined by the Godin leisure time questionnaire) with a mean score of 10.99 ± 1.38 .

Participants were divided into two equal groups: the experimental group (n=33) received LB with an individualized LCD program and the control group (n=33) followed the same diet program alone for 12 weeks. Insulin resistance was assessed by the HOMA-IR index; anthropometric measures [weight, BMI, and waist circumference (WC)]; inflammatory biomarkers (CRP, WBCs, lymphocytes, and ESR), and depression (recorded by the HAMD-17 scale) were assessed before and after the intervention.

Exclusion Criteria

Women were excluded from this study if they were: smokers, diabetics, alcoholics, uncontrolled hypertensives, receiving hormonal therapy, following weight reduction or exercise program at least six months prior to participation in this study, on medications known to affect their psychological states or bodyweight, phototherapy sensitive, having cognitive impairment, having malignant diseases or any cardiovascular disease, and having any additional factors that might affect our outcome measures or the intervention progression.

Randomization

Sixty-six eligible postmenopausal women were randomly assigned (1:1) to either the experimental group (LB with LCD) or the control group (LCD program only), utilizing block randomization with block sizes of 2, 4, and 6 *via* the R Software (version 2.11) to obtain balanced groups. The study statistician created the randomization list, which was then concealed in numbered envelopes in a blinded manner. Hence, both the participants and the clinician were unaware of the assigned intervention.

Eligibility

Initially, a total of eighty postmenopausal women were evaluated for eligibility; approximately fourteen women were excluded (ten met the exclusion criteria, two refused to participate, and two for other reasons). Six women were lost to follow-up for personal reasons, and only sixty women completed the trial and were included in the statistical analysis (Figure 1).

Intervention

LB

The experimental group received LB *via* a non-invasive laser watch that radiated photobiology infrared laser waves through bilateral nasal probes and specific wrist acupuncture point stimulation without registering any identified hazards after the intervention, which was operated according to the parameters⁷ shown in Table I.

Diet Program (LCD)

During the first six weeks of the study, both groups' diets were restricted by 500 kcal/d, and the mean energy intake was 1773.62 ± 41.70 kcal/d. In the final six weeks of the study, the diet was restricted to 1000 kcal/d of daily calorie requirements¹³, which were cal-



Figure 1. Consort flow diagram of this study.

culated using the Harris-Benedict equation for daily energy expenditure estimation¹⁴, and the mean energy intake was 1276.70 ± 41.93 kcal/ d¹⁵. The prescribed restricted balanced diet included 50-60% carbohydrates, 15-20% protein, 20-35% fat, and 25 g of fibers per day¹⁶. A nutritional consultant and a physiotherapist regularly contact participants on a regular basis to ensure their adherence to the prescribed diet program, avoidance of unsafe eating patterns, and maintenance of the same level of daily physical activity.

Primary Outcome Measures

Venous blood samples were collected at the beginning as well as the end of the 12-week study period in the outpatient clinic (nearly at 9:00 am after at least 12 hours of fasting) to analyze blood

glucose and insulin levels in order to calculate insulin sensitivity using the HOMA-IR index formula [fasting plasma glucose (mmol/l) × fasting serum insulin (mU/l)/22.5] and to measure the inflammatory biomarkers (WBCs count, lymphocytes, ESR, and CRP levels).

Depression

A depression assessment scale (HAMD-17item scale) was applied in our study with a maximum score of 52 to categorize the participants as normal, mild, moderate, or extreme depression based on scores of 0-7, 8-16, 17-23, and over 24, respectively.

Secondary Outcome Measures

All participants' BMI (kg/m²) was calculated by dividing their body mass (kg) by their heights

Characteristics		Experimental group (n =30)	Control group (n =30)	<i>p</i> -value	
	Mean \pm SD	66.10 ± 4.56	67.12 ± 5.06	- 0.482	
Age (yis)	Range	60.00-75.00	60.00-75.00		
Developed activity units	Mean \pm SD	10.90 ± 1.45	11.07 ± 1.31	0.642	
	Range	9.00-13.00	9.00-13.00		
Monstrual quala absonces (urs)	Mean \pm SD	10.83 ± 2.00	11.27 ± 2.26	0.435	
Wenstruar cycle absences (yrs)	Range	7.00-15.00	8.00-15.00	0.433	
Energy intelse (legel/d)	Mean \pm SD	2277.50 ± 45.69	2276.40 ± 37.99	- 0.020	
Energy intake (kcai/d)	Range	2200.00-2360.00	2230.00-2350.00	0.920	
Unight (am)	Mean \pm SD	153.21 ± 3.83	152.89 ± 3.24	0.725	
Height (Chi)	Range	147.00-161.00	148.00-160.00	0.725	
Weight (kg)	Mean \pm SD	84.93 ± 9.04	83.97 ± 8.59	0.674	
	Range	70.40-100.60	67.70-98.30	0.074	
$\mathbf{DM}(1, 1, 2)$	Mean \pm SD	35.99 ± 2.68	35.86 ± 2.71	0.849	
BIVII (kg/m²)	Range	30.80-39.90	30.10-39.70		
Weigt sime former ()	Mean \pm SD	104.62 ± 9.47	104.15 ± 8.79	0.942	
waist circumerence (ciri)	Range	88.60-120.60	88.70-120.50	0.843	
In sulin assistance	Mean \pm SD	2.96 ± 0.72	3.01 ± 0.66	0.702	
Insulin resistance	Range	1.97-4.99	1.96-4.90	0.792	
$CDD(m \sigma/L)$	Mean \pm SD	4.80 ± 0.63	5.08 ± 0.67	0.100	
CRP (mg/L)	Range	3.70-6.00	3.71-6.01	0.109	
ESD (mm/hr)	Mean \pm SD	16.60 ± 5.16	17.37 ± 4.86	0.55(
ESK (mm/nr)	Range	7.00-25.00	8.00-25.00	0.330	
$WDC_{2}(10^{9}/L)$	Mean \pm SD	9.19 ± 1.02	9.24 ± 1.03	0.951	
WBCS (107L)	Range	7.50-11.20	7.40-11.10	0.851	
Lymphocytes (10 ⁹ /L)	Mean \pm SD	36.00 ± 5.85	37.73 ± 6.31	0.274	
	Range	27.00-47.00	28.00-48.00	0.274	
Depression scale	Mean \pm SD	11.93 ± 0.40	11.83 ± 0.48	0.492	
	Range	10.89-13.14	10.88-13.13	0.482	
Education level					
1 st		4(13.3%)	4(13.3%)	0.000	
2 nd	N (0/)	3(10.0%)	3(10.0%)		
3 rd	IN (70)	8(26.7%)	8(26.7%)	0.998	
4 th		7(23.3%)	8(26.7%)		
5 th		8(26.7%)	7(23.3%)		

Table I. Baseline characteristics of study participants mean ± standard deviation (SD).

†BMI, Body mass index; CRP, C - reactive protein; ESR, Erythrocyte Sedimentation Rate; WBCs, White Blood Cells. Data represented as mean ± standard deviation (SD) and range (min-max) for continuous data and N (%) for categorical data.

(m²). Furthermore, WC was estimated during full expiration using an elastic tape midway between the last rib and the upper iliac crest border.

Estimation of Sample Size

With a 95% confidence interval, a total required sample size of 30 women in each group was calculated. A type I error rate of 0.05, and a type II error rate of 80% statistical power, a twotailed *t*-test (i.e., the difference between two independent means of two groups) was assumed to estimate moderate effect size, Cohen's d (0.5), and a drop-out rate of 5%.

Statistical Analysis

With sixty-six women enrolled in this study, we had 91% retention at 12 weeks, with sixty of the sixty-six women completing final evaluations (Figure 1). For subjects who had withdrawn, an intention-to-treat analysis was performed. The last observation carried forward method was used for data filling. Statistical analysis was conducted with SPSS 25 statistical software (IBM Corp., Armonk, NY, USA). The Shapiro-Wilk test was used to determine whether the data were normally distributed. Continuous data were described as mean \pm standard deviation (SD). The categorical data were expressed as absolute frequencies and percentages. Unadjusted comparisons of baseline characteristics were performed using independent samples *t*-test for continuous data and Chi-square tests for categorical data.

A mixed-repeated-measures analysis of variance (ANOVA) was applied to compare the mean values of variables between the experimental and control groups and between pre-and post-intervention in each group. Huynh-Feldt was undertaken when Mauchly's sphericity test denied the assumption of sphericity. The partial eta-squared $(\eta^2 p^2)$ effect size was calculated to assess the differences between and within the experimental and control groups. Bonferroni's test was used as a post hoc test to follow significant interactions or main effects, mean values of dependent variables for both groups, and pre-and post-intervention outcomes in each group. *p*-values lower than 0.05 were considered statistically significant.

Results

A total of sixty obese postmenopausal women were included in this study, with a mean age of 66.61 ± 4.80 (ranging between 60.00-75.00years), a mean weight between 84.45 ± 8.76 kg (ranging between 67.70-100.60 kg), and a mean BMI of 35.93 ± 2.67 kg/m² (ranging from 30.60-39.80 kg/m²). Thirty women received LB combined with LCD (the experimental group), while the remaining thirty women, serving as the control group, received LCD alone.

As displayed in Table II, there were no statistically significant differences between the experimental and control groups regarding qualitative and measured variables at baseline (p>0.05).

Table III demonstrates a significant difference within the experimental and control groups in all dependent variables before and after the intervention (p<0.001), along with a significant interaction between intervention type and time, Wilks' lambda (p<0.001) for all variables.

There was a significant interaction between intervention type and time regarding weight and BMI (p < 0.001, $\eta^2 p = 0.684$ and 0.938, respectively) and a significant main effect of the intervention (p < 0.001, $\eta^2 p = 0.212$ and 0.291, respectively). In the experimental group, we observed a significant decrease in weight and BMI after 12 weeks of follow-up by 13.14 kg and 11.28 kg/ m², respectively, compared to the control group, whose levels decreased by 6.36 kg and 6.41 kg/ m², respectively (p < 0.001, $\eta^2 p = 0.947$ and 0.995, respectively).

With respect to WC and IR, there was a significant interaction between intervention type and time (p<0.001, $\eta^2 p$ =0.962, p<0.001, $\eta^2 p$ =0.676, respectively). Also, there was a substantial main effect of time (p<0.001, $\eta^2 p$ =0.997, p<0.001, $\eta^2 p$ =0.918, respectively) and a significant main effect of intervention (p=0.023, $\eta^2 p$ =0.225, p=0.012, $\eta^2 p$ =0.240, respectively).

Regarding the CRP and ESR levels, there was a significant interaction between intervention type and time (p<0.001, $\eta^2 p$ =0.904, p<0.001, $\eta^2 p$ =0.791, respectively) and a substantial main effect of intervention (p<0.001, $\eta^2 p$ =0.201, p<0.001, $\eta^2 p$ =0.147, respectively). Time also had a substantial main effect (p<0.001, $\eta^2 p$ =0.979, p<0.001, $\eta^2 p$ =0.962, respectively).

In terms of WBCs and lymphocytes concentrations, a statistically significant reduction in the experimental group was observed (MD=-1.84 \pm 0.23 10⁹/L and MD=-8.13 \pm 1.43 10⁹/L, respectively), compared to the control group (MD=-0.67 \pm 0.11 10⁹/L and MD=-3.27 \pm 0.74 10⁹/L, respectively) after 12 weeks of follow-up (p < 0.001). Additionally, WBCs and lymphocytes concentrations (p<0.001) with a large effect size ($\eta^2 p$ = 0.914 and 0.825, respectively) revealed a significant main effect of time (p<0.001) with a large effect size ($\eta^2 p$ =0.980 and 0.963, respectively) and a significant main effect of intervention (p=0.015 and 0.008, respectively) with a large effect size ($\eta^2 p$ =0.219 and 0.116, respectively).

For the depression scale, there was a significant interaction between intervention type and time (p<0.001, $\eta^2 p$ =0.803) (Table III). Time (p<0.001, $\eta^2 p$ =0.932) and group (p<0.001, $\eta^2 p$ =0.297) had the main significant effect. Additionally, the experimental group experienced a significant reduction in the depression scale over time when compared to the control group (MD=-2.25 ± 0.50 vs. MD = -0.66 ± 0.27; p<0.001).

Discussion

The current study aimed to compare the effect of LB combined with a balanced LCD vs. LCD alone on IR, inflammatory biomarkers, and depression levels in obese postmenopausal women. The results showed an average reduction of the body weight -13.14% for the experimental group (p<0.001) vs. -6.36% for the control group. There

Variables		Pre-intervention	Post-intervention		% of improvement	Interaction (Group X Time)		Within groups (Time)		Between groups (groups)		<i>p</i> -value ^ь
					p-value"	<i>η</i> ² p	p-value ^a	η² p	p-value ^a	η² p		
Weight (kg)	Experimental group	84.93 ± 9.04	73.77 ± 8.94	-11.04 ± 2.78	↓13.14%	<0.001*	0.684	< 0.001*	0.947	0.040*	0.212 -	< 0.001*
	Control group	83.97 ± 8.59	78.63 ± 8.64	-5.33 ± 0.20	↓6.36%							< 0.001*
BMI (kg/m ²)	Experimental group	35.99 ± 2.68	31.93 ± 2.71	-4.06 ± 0.30	↓11.28%	<0.001*	0.938	<0.001*	0.995	0.029*	0.291 -	< 0.001*
	Control group	35.86 ± 2.71	33.56 ± 2.78	-2.30 ± 0.13	↓6.41%							< 0.001*
Waist	Experimental group	104.62 ± 9.47	90.09 ± 9.28	-14.52 ± 0.51	↓13.89%	< 0.001*	0.962	<0.001*	0.997	0.023*	0.225 -	< 0.001*
circumference (cm)	Control group	104.15 ± 8.79	96.27 ± 8.88	-7.87 ± 0.81	↓7.56%							< 0.001*
Insulin resistance	Experimental group	2.96 ± 0.72	2.26 ± 0.58	-0.70 ± 0.20	↓23.65%	< 0.001*	0.676	< 0.001*	0.918	0.012*	0.240 -	< 0.001*
	Control group	3.01 ± 0.66	2.73 ± 0.62	$\textbf{-0.28} \pm 0.06$	↓9.30%							< 0.001*
CRP (mg/L)	Experimental group	4.80 ± 0.63	3.72 ± 0.55	$\textbf{-}1.09\pm0.13$	↓22.5%	< 0.001*	0.904	< 0.001*	0.979	< 0.001*	0.201 -	< 0.001*
	Control group	5.08 ± 0.67	4.66 ± 0.63	$\textbf{-}0.42\pm0.08$	↓8.267%							< 0.001*
ESR (mm/hr)	Experimental group	16.60 ± 5.16	11.80 ± 4.50	-4.80 ± 0.92	↓28.92%	< 0.001*	0.791	<0.001*	0.962	0.046*	0.147 -	< 0.001*
	Control group	17.37 ± 4.86	15.23 ± 4.76	-2.13 ± 0.35	↓12.32%							< 0.001*
WBCs (10 ⁹ /L) $\frac{H}{C}$	Experimental group	9.19 ± 1.02	7.35 ± 0.84	-1.84 ± 0.23	↓20.02%	< 0.001*	0.914	< 0.001*	0.980	0.015*	0.219 -	< 0.001*
	Control group	9.24 ± 1.03	8.57 ± 1.05	-0.67 ± 0.11	↓7.25%							< 0.001*
Lymphocytes (10 ⁹ /L)	Experimental group	36.00 ± 5.85	27.87 ± 5.18	-8.13 ± 1.43	↓22.58%	< 0.001*	0.825	< 0.001*	0.963	0.008*	0.116 -	< 0.001*
	Control group	37.73 ± 6.31	34.47 ± 6.16	-3.27 ± 0.74	↓8.64%							< 0.001*
Depression scale	Experimental group	11.93 ± 0.40	9.68 ± 0.63	-2.25 ± 0.50	↓18.86%	< 0.001*	0.803	< 0.001*	0.932	< 0.001*	0.297 -	< 0.001*
	Control group	11.83 ± 0.48	11.16 ± 0.53	-0.66 ± 0.27	↓5.66%							< 0.001*

Table II. Comparison of all measured variables before and after 12 weeks, in both experimental and control groups mean ± standard deviation (SD).

‡BMI, Body mass index; CRP, C-Reactive Protein; ESR, Erythrocyte Sedimentation Rate; WBCs, White Blood Cells.

 Δ : Mean difference of post-pre value (MD). $\eta^2 p$, Partial Eta-Squared ranges from 0 to 1 (0.01=small, 0.06=medium, and 0.14=large effect-size).

a, Mixed repeated-measures ANOVA.
b, Post hoc using paired sample *t*-test.
*, Statistically significant at *p* <0.05.

was also a reduction in BMI, IR, inflammatory markers, and depression scores.

The current findings are compatible with previous studies^{8,9} which detected a reduction of fat deposits of about 6-12 inches of WC after LB. Jackson et al¹⁷ found that applying LB it resulted in a substantial reduction in body weight and BMI with p < 0.0005 and p < 0.001, respectively. Furthermore, in a study of seventy-four postmenopausal women with visceral obesity, Wozniak et al¹⁰ suggested that combining LCD with laser therapy reduced body weight, BMI, and waisthip ratio (WHR) more than LCD alone. Weight loss has been linked to the LB effect by increasing lipid metabolism¹⁸ and inducing an antioxidant effect on adipocytes, which contributes to the production of adiponectin¹⁹. In addition, the LCD decreases body weight by reducing the amount of energy input⁵.

Our results regarding inflammatory biomarkers (ESR, CRP, and WBCS) were supported by Thomas et al²⁰, who found a substantial decrease in the inflammatory markers (WBCs, lymphocytes, eosinophils, ESR, and CRP) after LB sessions. LB has also been shown to lower ESR levels in people with inflammatory arthritis²¹, possibly due to diminished plasma fibrinogen²⁰. It has been shown that after LB intervention, the amount of cyclic adenosine monophosphate (cAMP)⁷ increased, which acts as an inflammatory modulator in many cells²².

The LB could reduce intracellular reactive oxygen species (ROS) by inhibiting prostaglandin production and subsequent biochemical reactions²³. A low-calorie diet was found to have a greater anti-inflammatory benefit⁵, where dietary fibers were inversely correlated with serum CRP concentrations and inflammatory cytokines¹⁰. Moreover, lower sodium and saturated fat intake improved the lipid profile and blood pressure control⁵. Also, higher fiber consumption and fewer sugary products resulted in lower blood glucose levels²⁴.

Regarding IR, Sene-Fiorese et al²⁵ stated that LB combined with LCD diet led to a more significant reduction of the HOMA-IR index (p<0.0001), which is congruent with our findings. LB affects insulin sensitivity by reducing the intercellular levels of inflammatory cytokines released from adipocytes and contributes to IR²⁶. Additionally, laser therapy improves cation transport across the cell membrane, disrupted in hyperinsulinemia or IR²². Accordingly, a calorie-reduced diet strongly correlates to weight loss and enhanced insulin sensitivity²⁷.

As a result of mitochondrial malfunction, postmenopausal women are more susceptible to depression, as evidenced by lower energy levels⁴. LB enhances the mitochondrial activity and adenosine triphosphate (ATP) generation, which can help alleviating depression symptoms²⁶. Furthermore, a well-balanced diet rich in fruits and vegetables increases the antioxidant effect, reducing free radicals and protecting brain cells²⁷.

Morries et al²⁸ found that LB improves memory and decreases depression, headaches, insomnia, and anxiety in chronic traumatic brain injury patients. Moreover, Cohen et al²⁹ found that LB lowers postmenopausal women's mental and behavioral difficulties, which is congruent with our findings. Linde et al³⁰ found a relationship between LCD intervention and improvements in depressive symptoms in obese women.

Limitations

This study evaluated the effect of LB with LCD on the physical parameters and the psychological status in obese postmenopausal women. Moreover, we highlighted the benefits of non-invasive LB in sedentary subjects who did not prefer to exercise or abstain from surgical or pharmacological adverse effects.

Despite the promising results, this research was focused only on one form of LB and one dietary weight loss program in obese postmenopausal women. Future studies are needed to investigate various dietary regimens and LB wavelengths in different populations and health conditions to enhance the generalization of the results. Participants' selection was limited to women with no cardiovascular disorders or medical problems. Women with surgical menopause and those on hormonal therapy were excluded, which may cause a limited variation in the study results.

Conclusions

The current study's findings support the combined effect of LB with LCD in decreasing inflammatory biomarkers, IR, and depression in postmenopausal women, paving the way to apply the current approach to high-risk patients, including diabetic and hypertensive patients.

Contribution Statement

M. M. and E. N. contributed to data curation, methodology, investigation, conceptualization, M. R., H. E., and N. A. participated in methodology, editing, supervision, validation, writing-original draft, and all authors read and approved the final version of the manuscript and agreed with the order of presentation of the authors.

Financial Support

This study received no specific grant from any funding agency in the public, commercial, or non-profit sectors.

Acknowledgments

The authors thank all individuals who supported this study; in particular, they are grateful to Ebthall Mohamed for her help in data analysis and interpretation. This trial was registered at www.ClinicalTrials.gov, identifier number: NCT04477109.

Conflict of Interest

The authors state that they have no competing interests.

References

- 1) van Dijk GM, Kavousi M, Troup J, Franco OH. Health issues for menopausal women: the top 11 conditions have common solutions. Maturitas 2015; 80: 24-30.
- Elbahrawe R, Fahim A, Abdou L, Abbas A, Saleh, L. Quality of Life among Postmenopausal Egyptian Women: A Cross-Sectional Study. Archives of Community and Family Medicine 2020; 12: 42-49.
- Chu MC, Cosper P, Orio F, Carmina E, Lobo RA. Insulin resistance in postmenopausal women with metabolic syndrome and the measurements of adiponectin, leptin, resistin, and ghrelin. Am J Obstet Gynecol 2006; 194: 100-104.
- Timur S, Sahin NH. The prevalence of depression symptoms and influencing factors among perimenopausal and postmenopausal women. Menopause 2010; 17: 545-551.
- Eckel RH. Clinical practice. Nonsurgical management of obesity in adults,". N Engl J Med 2008; 358: 1886-1950.
- 6) Cho SH, Lee JS, Thabane L, Lee J, "Acupuncture for obesity: a systematic review and meta-analysis,". Int J Obes 2009; 33: 183-196.
- Litscher D and Litscher G. A Laser Watch for Simultaneous Laser Blood Irradiation and Laser Acupuncture at the Wrist. Integrative Medicine Int 2016; 3: 75-81.
- Tseng CC, Tseng A, Chang CH. Effect of laser acupuncture on obesity: study protocol for a randomized controlled trial. Trials 2015; 16: 217-223.

- Croghan IT, Hurt RT, Schroeder DR, Fokken SC, Jensen MD, Clark MM, Ebbert JO. Low-level laser therapy for weight reduction: a randomized pilot study. Lasers Med Sci 2020; 35: 663-675.
- 10) Wozniak P, Stachowiak G, Piêta-Doliñska A, Oszukowski P. Laser acupuncture and low-calorie diet during visceral obesity therapy after menopause. Acta Obstet Gynecol Scand 2003; 82: 69-73.
- 11) Whittaker P, "Laser acupuncture: past, present, and future,". Lasers Med Sci 2004; 19: 69-80.
- 12) Imayama I, Ulrich CM, Alfano CM, Wang C, Xiao L, Wener MH, Campbell KL, Duggan C, Foster-Schubert KE, Kong A, Mason CE, Wang CY, Blackburn GL, Bain CE, Thompson HJ, McTiernan A. Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res 2012; 72: 2314-2326.
- 13) Koliaki C, Spinos T, Spinou M, Brinia ME, Mitsopoulou D, Katsilambros N. Defining the Optimal Dietary Approach for Safe, Effective and Sustainable Weight Loss in Overweight and Obese Adults. Healthcare (Basel) 2018; 6: 73-85.
- 14) Roza AM, Shizgal HM. The Harris Benedict equation reevaluated: resting energy requirements and the body cell mass. Am J Clin Nutr 1984; 40: 168-182.
- Osterkamp LK. Current perspective on assessment of human body proportions of relevance to amputees. J Am Diet Assoc 1995; 95: 215-218.
- 16) van Lee L, Geelen A, van Huysduynen EJ, de Vries JH, van't Veer P, Feskens EJ. The Dutch Healthy Diet index (DHD-index): an instrument to measure adherence to the Dutch Guidelines for a Healthy Diet. Nutr J 2012; 11: 49-51.
- 17) Jackson RF, Roche GC, Shanks SC. A double-blind, placebo-controlled randomized trial evaluating the ability of low-level laser therapy to improve the appearance of cellulite. Lasers Surg Med 2013; 45: 141-147.
- 18) Neira R, Arroyave J, Ramirez H, Ortiz CL, Solarte E, Sequeda F, Gutierrez MI. Fat liquefaction: effect of low-level laser energy on adipose tissue. Plast Reconstr Surg 2002; 110: 912-935.
- 19) Jankowski M, Gawrych M, Adamska U, Ciescinski J, Serafin Z, Czajkowski R. Low-level laser therapy (LLLT) does not reduce subcutaneous adipose tissue by local adipocyte injury but rather by modulation of systemic lipid metabolism. Lasers Med Sci 2017; 32: 475-479.
- 20) Thomas MM, Ahmed Kamel IE, Mohamed NH, Ramadan A, El-Bassyouni HT. Osteoarthritis in patients with familial Mediterranean fever: genetic basis and anti-inflammatory effect of laser acupuncture. Middle East J Med Genet 2019; 8: 33-41.
- 21) Attia AM, Ibrahim FA, Abd El-Latif NA, Aziz SW, Elwan AM, Abdel Aziz AA, Elgendy A. Therapeutic antioxidant and anti-inflammatory effects of laser acupuncture on patients with rheumatoid arthritis. Lasers Surg Med 2016; 48: 490-497.

- 22) de Lima FM, Moreira LM, Villaverde AB, Albertini R, Castro-Faria-Neto HC, Aimbire F. Low-level laser therapy (LLLT) acts as cAMP-elevating agent in acute respiratory distress syndrome. Lasers Med Sci 2011; 26: 389-400.
- 23) Lim W, Kim J, Kim S, Karna S, Won J, Jeon SM, Kim SY, Choi Y, Choi H, Kim O. Modulation of lipopolysaccharide-induced NF-κB signaling pathway by 635 nm irradiation via heat shock protein 27 in human gingival fibroblast cells. Photochem Photobiol 2013; 89: 199-207.
- 24) Ahmed T, Das SK, Golden JK, Saltzman E, Roberts SB, Meydani SN. Calorie restriction enhances T-cell-mediated immune response in adult overweight men and women. J Gerontol A Biol Sci Med Sci 2009; 64: 1107-1113.
- 25) Sene-Fiorese M, Duarte FO, de Aquino Junior AE, Campos RM, Masquio DC, Tock L, de Oliveira Duarte AC, Dâmaso AR, Parizotto NA, Bagnato VS. The potential of phototherapy to reduce body fat, insulin resistance and "metabolic inflexibility" related to obesity in women undergoing weight loss treatment. Lasers Surg Med 2015; 47: 634-642.
- 26) Silva G, Ferraresi C, de Almeida RT, Motta ML, Paixão T, Ottone VO, Fonseca IA, Oliveira MX,

Rocha-Vieira E, Dias-Peixoto MF, Esteves EA, Coimbra CC, Amorim FT, de Castro Magalhães F. Infrared photobiomodulation (PBM) therapy improves glucose metabolism and intracellular insulin pathway in adipose tissue of high-fat fed mice. Lasers Med Sci 2018; 33: 559-571.

- 27) Li T, Chen K, Liu G, Huang LP, Chen L, Wang QW, Hu CL, Hou LJ. Calorie restriction prevents the development of insulin resistance and impaired lipid metabolism in gestational diabetes offspring. Pediatr Res 2017; 81: 663-671.
- 28) Morries LD, Cassano P, Henderson TA. Treatments for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy. Neuropsychiatr Dis Treat 2015; 11: 2159-2175.
- 29) Cohen SM, Rousseau ME, Carey BL. Can acupuncture ease the symptoms of menopause? Holist Nurs Pract 2003; 17: 295-299.
- 30) Linde JA, Simon GE, Ludman EJ, Ichikawa LE, Operskalski BH, Arterburn D, Rohde P, Finch EA, Jeffery RW. A randomized controlled trial of behavioral weight loss treatment versus combined weight loss/depression treatment among women with comorbid obesity and depression. Ann Behav Med 2011; 41: 119-130.